Laboratorios Farmaceuticos Rovi, S.A.

Laboratorios Farmaceuticos Rovi, S.A.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. has 51.14M shares outstanding.

As of June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. maintains a current ratio of 2.05, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.02, indicating elevated leverage, while an interest coverage ratio of 68.05 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. posted a return on equity (ROE) of 29.30, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 23.99 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 18.55, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 24.66, useful for judging operating efficiency across full business cycles. The company generates approximately 347,713.03 in revenue per employee across its workforce of 2,223.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.87 indicates how many times Laboratorios Farmaceuticos Rovi, S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. recorded 50.17M in income tax expense. That works out to an effective tax rate of 21.33, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 235.21M, leaving 185.18M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. generated 773.05M in revenue and converted that into 185.18M in net income, yielding earnings per share of 3.62. EBITDA reached 271.57M, while operating income came in at 175.62M.

As of June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. holds 128.07M in cash and equivalents against 107.69M in total debt, resulting in a net debt position of -126.97M. Total book value stands at 700.62M, with working capital of 291.41M providing operational flexibility.

Laboratorios Farmaceuticos Rovi, S.A. produced 253.32M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -77.40M in capital expenditures, free cash flow totaled 175.92M - equivalent to 3.44 per share.

Over the twelve months ended June 30, 2026, Laboratorios Farmaceuticos Rovi, S.A. posted a gross margin of 66.17, reflecting its pricing power and cost economics. The operating margin of 22.72 and net profit margin of 23.95 provide insight into operational efficiency.